FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4317891428> ?p ?o ?g. }

• W4317891428 endingPage "578" @default.
• W4317891428 startingPage "578" @default.
• W4317891428 abstract "578 Background: Immune checkpoint inhibitors (CPIs) targeting PD-1/PD-L1 have become established treatments for advanced hepatocellular carcinoma (aHCC) but yield low objective response rates (ORRs) in treated patients (pts). Dual inhibition of LAG-3 and PD-1 pathways has demonstrated synergy in activating T-cells and improving immune response. Tebotelimab, also known as MGD013, is a bispecific tetravalent DART molecule that can bind both PD-1 and LAG-3. We initiated an open-label, single-arm, phase 1/2 dose escalation and expansion study to assess the safety and efficacy of tebotelimab in pts with aHCC. Methods: Eligible pts with aHCC who received ≥1 prior systemic treatment with or without prior CPI exposure were enrolled. The dose escalation phase evaluated doses at 120, 240, 400, and 600 mg. Tebotelimab was administered intravenously once every two weeks (Q2W) on days 1 and 15 of each 28-day cycle. The dose expansion phase consisted of one CPI-experienced cohort and one CPI-naïve cohort, both treated at recommended phase 2 dose (RP2D). Primary endpoints were safety for the escalation phase, and safety and ORR per RECIST v1.1 for the expansion phase. Investigator-assessed efficacy results are reported. Results: At data cut-off as of 27 April 2022, 13 pts received tebotelimab in the escalation phase. No dose-limiting toxicity was observed and RP2D was determined as 600 mg Q2W. In the expansion phase, 69 pts (CPI-experienced 33, CPI-naïve 36) were enrolled (median age, 57.0 years; male, 87.0%; ECOG 1, 58.0%; BCLC Stage C, 89.9%; and HBV etiology, 84.1%). Thirteen (18.8%) pts had Grade ≥3 treatment-related adverse events (TRAEs), most commonly hepatic function abnormal (n=3), amylase increased (n=2), and aspartate aminotransferase increased (n=2). Serious TRAEs occurred in nine (13.0%) pts, immune-related adverse events in 30 (43.5%), TRAEs leading to treatment discontinuation in five (7.2%), and treatment-related death in one (1.4%). Of the 30 evaluable pts in the CPI-experienced cohort, one achieved confirmed partial response (PR) and 14 achieved stable disease (SD), with a 3.3% ORR and a 50.0% disease control rate (DCR); of the 30 evaluable pts in the CPI-naïve cohort, four achieved confirmed PR and 10 achieved SD, with a 13.3% ORR and a 46.7% DCR. Median progression-free survival was 2.4 and 3.1 months for CPI-experienced and CPI-naïve cohorts, respectively, with median overall survival not reached in both. Conclusions: Tebotelimab demonstrated a manageable safety profile in pts with aHCC. Antitumor activity, mainly as disease stabilization, was observed in both the CPI-naïve setting and the CPI-experienced setting. No additional clinical trials are planned at this time. Clinical trial information: NCT04212221 ." @default.
• W4317891428 created "2023-01-25" @default.
• W4317891428 creator A5000432967 @default.
• W4317891428 creator A5016590125 @default.
• W4317891428 creator A5023913868 @default.
• W4317891428 creator A5031852092 @default.
• W4317891428 creator A5046173951 @default.
• W4317891428 creator A5046498356 @default.
• W4317891428 creator A5048541371 @default.
• W4317891428 creator A5049658960 @default.
• W4317891428 creator A5057209439 @default.
• W4317891428 creator A5061762485 @default.
• W4317891428 creator A5073108755 @default.
• W4317891428 creator A5076731937 @default.
• W4317891428 creator A5083245206 @default.
• W4317891428 creator A5086033939 @default.
• W4317891428 creator A5086047610 @default.
• W4317891428 creator A5086559201 @default.
• W4317891428 creator A5087661837 @default.
• W4317891428 creator A5089201081 @default.
• W4317891428 date "2023-02-01" @default.
• W4317891428 modified "2023-10-18" @default.
• W4317891428 title "Tebotelimab, a PD-1/LAG-3 bispecific antibody, in patients with advanced hepatocellular carcinoma who had failed prior targeted therapy and/or immunotherapy: An open-label, single-arm, phase 1/2 dose-escalation and expansion study." @default.
• W4317891428 doi "https://doi.org/10.1200/jco.2023.41.4_suppl.578" @default.
• W4317891428 hasPublicationYear "2023" @default.
• W4317891428 type Work @default.
• W4317891428 citedByCount "2" @default.
• W4317891428 countsByYear W43178914282023 @default.
• W4317891428 crossrefType "journal-article" @default.
• W4317891428 hasAuthorship W4317891428A5000432967 @default.
• W4317891428 hasAuthorship W4317891428A5016590125 @default.
• W4317891428 hasAuthorship W4317891428A5023913868 @default.
• W4317891428 hasAuthorship W4317891428A5031852092 @default.
• W4317891428 hasAuthorship W4317891428A5046173951 @default.
• W4317891428 hasAuthorship W4317891428A5046498356 @default.
• W4317891428 hasAuthorship W4317891428A5048541371 @default.
• W4317891428 hasAuthorship W4317891428A5049658960 @default.
• W4317891428 hasAuthorship W4317891428A5057209439 @default.
• W4317891428 hasAuthorship W4317891428A5061762485 @default.
• W4317891428 hasAuthorship W4317891428A5073108755 @default.
• W4317891428 hasAuthorship W4317891428A5076731937 @default.
• W4317891428 hasAuthorship W4317891428A5083245206 @default.
• W4317891428 hasAuthorship W4317891428A5086033939 @default.
• W4317891428 hasAuthorship W4317891428A5086047610 @default.
• W4317891428 hasAuthorship W4317891428A5086559201 @default.
• W4317891428 hasAuthorship W4317891428A5087661837 @default.
• W4317891428 hasAuthorship W4317891428A5089201081 @default.
• W4317891428 hasConcept C126322002 @default.
• W4317891428 hasConcept C143998085 @default.
• W4317891428 hasConcept C197934379 @default.
• W4317891428 hasConcept C203092338 @default.
• W4317891428 hasConcept C2778019345 @default.
• W4317891428 hasConcept C535046627 @default.
• W4317891428 hasConcept C71924100 @default.
• W4317891428 hasConcept C72563966 @default.
• W4317891428 hasConcept C90924648 @default.
• W4317891428 hasConceptScore W4317891428C126322002 @default.
• W4317891428 hasConceptScore W4317891428C143998085 @default.
• W4317891428 hasConceptScore W4317891428C197934379 @default.
• W4317891428 hasConceptScore W4317891428C203092338 @default.
• W4317891428 hasConceptScore W4317891428C2778019345 @default.
• W4317891428 hasConceptScore W4317891428C535046627 @default.
• W4317891428 hasConceptScore W4317891428C71924100 @default.
• W4317891428 hasConceptScore W4317891428C72563966 @default.
• W4317891428 hasConceptScore W4317891428C90924648 @default.
• W4317891428 hasIssue "4_suppl" @default.
• W4317891428 hasLocation W43178914281 @default.
• W4317891428 hasOpenAccess W4317891428 @default.
• W4317891428 hasPrimaryLocation W43178914281 @default.
• W4317891428 hasRelatedWork W1570838273 @default.
• W4317891428 hasRelatedWork W2337719538 @default.
• W4317891428 hasRelatedWork W2385390897 @default.
• W4317891428 hasRelatedWork W2404951810 @default.
• W4317891428 hasRelatedWork W2410885201 @default.
• W4317891428 hasRelatedWork W2417822880 @default.
• W4317891428 hasRelatedWork W2418745692 @default.
• W4317891428 hasRelatedWork W2809701302 @default.
• W4317891428 hasRelatedWork W3172842848 @default.
• W4317891428 hasRelatedWork W628600844 @default.
• W4317891428 hasVolume "41" @default.
• W4317891428 isParatext "false" @default.
• W4317891428 isRetracted "false" @default.
• W4317891428 workType "article" @default.